Kalamazoo, Michigan - December 2, 2011 - Stryker Corporation (NYSE:SYK) announced today that Stryker Neurovascular and its Concentric Medical (Concentric) business has completed enrollment of the TREVO 2 trial. The TREVO 2 trial has enrolled 178 patients in 27 institutions in the United States and Europe. Concentric obtained IDE approval for the trial in December 2010 and began enrollment in the TREVO 2 trial in February of 2011. The company has asked sites to continue to follow all enrolled patients through 90 days per the protocol.
TREVO 2 is a pivotal, randomized clinical trial investigating the safety and efficacy of Concentric's Trevo® Retriever for removing clot from ischemic stroke patients as compared to Concentric's first generation retriever, the Merci® device. The Trevo Retriever is the first device utilizing Stentriever(TM) technology, a novel method for retrieving clot from the neurovasculature of ischemic stroke patients.
The TREVO 2 data will be used in a 510k submission to the U.S. Food and Drug Administration to seek clearance of the Trevo® Pro 4 device.
Concentric Medical was acquired by Stryker Corporation on October 3, 2011.
Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives. For more information about Stryker, please visit http://www.stryker.com/.
Contacts
For investor inquiries please contact:
Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com
HUG#1568505